16th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160106724 | HUMAN THERAPEUTIC AGENTS - Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers. | 2016-04-21 |
20160106725 | Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity - We describe a bis-benzylidine piperidone, RA190, which covalently binds to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma lines, even those resistant to bortezomib, were sensitive to RA190 via ER stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After p.o. or i.p. dosing of mice, RA190 distributed to plasma and major organs excepting brain, and potently inhibited proteasome function in skin and muscle. RA190 administration i.p. profoundly reduced growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retarded HPV+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses, suggesting its therapeutic potential. The bis-benzylidine piperidone RA190 is a new orally-available proteasome inhibitor. Multiple myeloma, cervical and ovarian cancers are particularly sensitive to RA190. | 2016-04-21 |
20160106726 | PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCY - Pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients:
| 2016-04-21 |
20160106727 | COMPOSITION AND METHOD FOR THE TREATMENT OF NEURODEGENERATION - A composition and method for the treatment of neurodegeneration and brain-derived neurotrophic factor. The composition and method comprising providing paroxetine, simvastatin, and optionally, an antioxidant. | 2016-04-21 |
20160106728 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE - Compounds, pharmaceutical compositions, and methods for treating anemia β-thalassemia anemia or sickle cell anemia. | 2016-04-21 |
20160106729 | Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof - The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed. | 2016-04-21 |
20160106730 | Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof - The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed. | 2016-04-21 |
20160106731 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF - The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. | 2016-04-21 |
20160106732 | Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof - The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed. | 2016-04-21 |
20160106733 | Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof - The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed. | 2016-04-21 |
20160106734 | Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof - The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed. | 2016-04-21 |
20160106736 | DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA - The present invention provides a method of providing pain relief in a human subject in need thereof comprising administering (R)-dihydroetorphine to said subject, wherein said (R)-dihydroetorphine is administered in a dose of at least 0.01 μg/kg, preferably at least 0.05 μg/kg, and the level of respiratory depression in said subject is 65 or less % relative to the baseline level pre-administration of (R)-dihydroetorphine. | 2016-04-21 |
20160106737 | Extended Release Abuse Deterrent Liquid Fill Dosage Form - The present disclosure relates to an oral, extended release, abuse deterrent dosage form containing a controlled release agent, a second agent and/or polyethylene glycol, and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is stable at high temperatures and abuse deterrent to oral and parenteral administration via dose dumping, extraction, and purification. The present disclosure also relates to processes of preparing the dosage form. | 2016-04-21 |
20160106738 | Treating Pain In Patients With Hepatic Impairment - An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment | 2016-04-21 |
20160106739 | Treating Pain In Patients With Hepatic Impairment - An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment | 2016-04-21 |
20160106740 | Treating Pain In Patients With Hepatic Impairment - An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment | 2016-04-21 |
20160106741 | ORAL PHARMACEUTICAL COMPOSITION FOR INCREASING HYPOXIA TOLERANCE - The present invention relates to an oral pharmaceutical composition for increasing hypoxia tolerance, characterized in that the pharmaceutical composition comprises active ingredient L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, active ingredient trimetazidine or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary material, and 100:1 is the weight ratio of L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof and trimetazidine or pharmaceutically acceptable salt thereof. | 2016-04-21 |
20160106742 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY - Described herein are methods for using compounds that activate pyruvate kinase. | 2016-04-21 |
20160106743 | TOPOISOMERASE II POISONS AND METHODS OF MAKING AND USING SAME - Disclosed herein are compositions of Formula I and an optional anticancer drug. Also disclosed herein are methods of treating or preventing cancer using the same. | 2016-04-21 |
20160106744 | METHODS OF INCREASING TEAR PRODUCTION - Described herein are methods and pharmaceutical formulations for increasing tear production. | 2016-04-21 |
20160106745 | DRY EYE TREATMENTS - Described herein are methods and pharmaceutical formulations for treating dry eye disease. | 2016-04-21 |
20160106746 | PHARMACEUTICAL FORMULATIONS FOR TREATING OCULAR CONDITIONS - Described herein are pharmaceutical formulations for treating ocular conditions. | 2016-04-21 |
20160106747 | TREATING POSTOPERATIVE MECHANICAL STRESS WITH AN ECTOINE - A method of treatment of a patient suffering from postoperative inflammatory stress and pain caused by mechanical impact exerted on portions of the body of the patient that causes damaged tissue wherein the inflammatory stress and pain of the operation outlast the healing of damaged tissue and which is not related to, or caused by, uncontrolled proteolysis. The treatment comprises administering a tetrahydropyrimidine selected from ectoine and/or hydroxyectoine to the patient. | 2016-04-21 |
20160106748 | PHARMACEUTICAL GASTRO-RETENTIVE SOLID ORAL DOSAGE FORM OF NILOTINIB - The present invention relates to a pharmaceutical gastro-retentive solid oral dosage form comprising nilotinib as the active ingredient. The invention is further related to methods of preparing said dosage form. | 2016-04-21 |
20160106749 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS - The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds. | 2016-04-21 |
20160106750 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. | 2016-04-21 |
20160106751 | SMALL MOLECULAR INHIBITORS OF RAD51 RECOMBINASE AND METHODS THEREOF - The invention includes compositions comprising a selective small-molecule inhibitor of RAD51 recombinase and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention. | 2016-04-21 |
20160106752 | Use of CB1 Antagonists and/or Inverse Agonists for the Preparation of Drugs that Increase Motor Neuron Excitability - Use of a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of a CB1 antagonist/ inverse agonist receptors, and to the use of a pharmaceutical composition which comprises a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level. | 2016-04-21 |
20160106753 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives - The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, | 2016-04-21 |
20160106754 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS - The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds. | 2016-04-21 |
20160106755 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 2016-04-21 |
20160106756 | BENZODIAZEPINES FOR TREATING SMALL CELL LUNG CANCER - The present invention relates to the use of a benzodiazepine compound, and its use in the treatment of cancer, particularly small cell lung cancer. | 2016-04-21 |
20160106757 | OPHTHALMIC SOLUTIONS - An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 α or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative. | 2016-04-21 |
20160106758 | Transdermal Delivery - Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval. | 2016-04-21 |
20160106759 | Transdermal Delivery - Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval. | 2016-04-21 |
20160106760 | Topically Active Steroids for Use In Interstitial Pulmonary Fibrosis - The present invention features methods of delivering corticosteroids or metabolites thereof for treating inflammatory conditions otherwise difficult to cure with topical administration. | 2016-04-21 |
20160106761 | Ophthalmologic Irrigation Solutions and Method - Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier. | 2016-04-21 |
20160106762 | VITAMIN D RECEPTOR/SMAD GENOMIC CIRCUIT GATES FIBROTIC RESPONSE - The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis. | 2016-04-21 |
20160106763 | ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - The present invention relates to a pharmaceutical composition which includes a HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid in a manner to minimize interaction of acetylsalicylic acid with the statin, for use in the prevention or treatment of cardiovascular diseases. | 2016-04-21 |
20160106764 | Doxycycline Formulations, and Methods of Treating Rosacea - The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean C | 2016-04-21 |
20160106765 | Carbidopa and L-Dopa Prodrugs and Methods of Use - The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease. | 2016-04-21 |
20160106766 | SOLID COMPOSITION FOR ORAL ADMINISTRATION CONTAINING IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND VITAMIN D - An improved solid pharmaceutical composition for oral administration comprising ibandronic acid or a pharmaceutically acceptable salt thereof, vitamin D and medium chain triglycerides or totally or partially hydrogenated oils which confer desirable physico-chemical properties to a solid formulation for oral administration suitable for the treatment of bone diseases and disorders of calcium metabolism. | 2016-04-21 |
20160106767 | USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF BREAST CANCER - The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-α/IKK-β, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells. | 2016-04-21 |
20160106768 | LYSOPHOSPHOLIPIDS AND LYSOPHOSPHOLIPID ANALOGUES AGAINST HONEYBEE BROOD DISEASES - The present invention refers to a compound selected from the group consisting of a lysophospholipid and a lysophospholipid analogue for use in the treatment or prophylaxis of honeybee brood diseases, in particular American foulbrood and European foulbrood. The invention also refers to a diet composition, a sprayable composition, a dipping solution for brood combs, a beeswax composition and liposomal and microsphere- or nanosphere-based compositions, comprising a compound according to the invention, for use in the treatment or prophylaxis of bee brood diseases. | 2016-04-21 |
20160106769 | COMPOUNDS AND METHODS FOR ENHANCING ERYTHROPOIESIS - Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (I) indicated below, in which R is a glucosyl group. In addition to having an erythropoiesis effect, the compound of the formula (I) is effective in enhancing erythropoietin formation, and increasing kidney function and expression of hepatocyte growth factor. The method includes the step of administering an effective amount of the compound of the formula (I) to a subject in need thereof and thereby results in an enhancement of erythropoiesis. | 2016-04-21 |
20160106770 | EPIGENETIC MECHANISMS OF ANTI-FIBROTIC ACTION FOR THE LIVER - This invention demonstrates the therapeutic efficacy of Yang-Gan-Wan (YGW) and its active components, especially in the formulation provided by Sheng-Pu Pharmaceutials, Inc., for treating and preventing liver fibrosis. This invention further demonstrates MeCP2 is an important therapeutic target for YGW and its active ingredients' action against liver fibrosis and cirrhosis. | 2016-04-21 |
20160106771 | THERAPIES FOR CARDIOMYOPATHY - The present invention relates to therapies and therapeutic agents for use in the treatment of cardiomyopathies. In particular, the invention is concerned with, but not limited to therapies and therapeutic agents for use in the treatment of hypertrophic cardiomyopathy. Such therapeutic agents comprise hypomethylating agents. | 2016-04-21 |
20160106772 | CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES - Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis. | 2016-04-21 |
20160106773 | TREATMENT FOR DISEASES RELYING ON DISCOVERY THAT THIOREDOXIN MEDIATES NITRIC OXIDE RELEASE IN CELLS - Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine. | 2016-04-21 |
20160106774 | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING PIROXICAM AND HYALURONIC ACID FOR THE TREATMENT OF OSTEOARTHRITIS - A pharmaceutical composition for the treatment of osteoarthritis comprising piroxicam or pharmaceutically acceptable salt thereof and hyaluronic acid or pharmaceutically acceptable salt thereof at a specific ratio is provided. The composition generates synergistic effect on both anti-inflammatory and analgesic effects simultaneously. The pharmaceutical composition contains 0.25-10.0 wt % of piroxicam or its pharmaceutically acceptable salt and 0.5-5.0 wt % of hyaluronic acid or its pharmaceutically acceptable salt, wherein the weight ratio between piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt is between 1:1 and 1:3. | 2016-04-21 |
20160106775 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION - Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction. | 2016-04-21 |
20160106776 | FEED SUPPLEMENT AND ITS USE - The present invention relates to feed supplements comprising vitamins and canthaxanthin and the use of such supplements for improving performance and health in poultry, in particular in poultry pullets. It has been found surprisingly that feed additive compositions as hereinafter defined improves immune status, bone and skeletal development, flock uniformity, growth and feed conversion of pullets. The feed additive composition according to the present invention comprises canthaxanthin, at least one vitamin selected from the group consisting of vitamin C and vitamin E, a trace mineral, in particular selenium, and optionally a mixture of at least two compounds selected from the group consisting of thymol, eugenol, vanillin and γ-terpinene. | 2016-04-21 |
20160106777 | NOVEL COMPOSITION METHOD OF USING THE SAME FOR THE TREATMENT OF LYME DISEASE - A composition for treating Lyme disease caused by | 2016-04-21 |
20160106778 | A MULTIPART FLUID SYSTEM AND A SYSTEM FOR CITRATE ANTICOAGUALATION IN AN EXTRACORPOREAL BLOOD CIRCUIT - The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and ≧10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit. | 2016-04-21 |
20160106779 | NEUTROPHIL-DEPLETED WHOLE BLOOD AND PLATELET RICH PLASMA COMPOSITIONS - A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted. | 2016-04-21 |
20160106780 | Methods and Compositions for Optimized Expansion and Implantation of Mesenchymal Stem Cells - Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (MSCs) to a patient in need of MSCs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets. | 2016-04-21 |
20160106781 | HIGH TELOMERASE ACTIVITY BONE MARROW MESENCHYMAL STEM CELLS, METHODS OF PRODUCING THE SAME AND PHARMACEUTICALS AND TREATMENT METHODS BASED THEREON - Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34 | 2016-04-21 |
20160106782 | WOUND HEALING AND TISSUE ENGINEERING - The present invention is directed to wound healing scaffolds cografted with a population of stem cells, wherein the population of stem cells are ABCB5+ stem cells. The scaffolds are, for instance, collagen glycosaminoglycan scaffolds. | 2016-04-21 |
20160106783 | METHOD FOR THE ANTI-SENESCENCE OF AND/OR REJUVENATING STEM CELLS - A method for the anti-senescence of and/or rejuvenating a stem cell is provided. The method comprising treating the stem cell with trans-cinnamaldehyde (TC). A kit is also provided. The kit comprising (1) a first part, comprising a stem cell; (2) a second part, comprising TC; and (3) a culture medium of the stem cell, placed in at least one of the first part, the second part, and a third part. In addition, a method for stem cell therapy is provided. The method comprising administering to a subject in need an effective amount of a stem cell, wherein the stem cell has been treated with TC before being administered. | 2016-04-21 |
20160106784 | ANGIOGENESIS USING PLACENTAL STEM CELLS - Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells. | 2016-04-21 |
20160106785 | UMBILICAL CORD PRODUCTS - Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM. | 2016-04-21 |
20160106786 | ENVIRONMENTAL CLOSTRIDIAL BACTERIOTHERAPY AND RELATED FORMULATIONS AND METHODS OF MANUFACTURE AND USE - Compositions and methods for inhibiting | 2016-04-21 |
20160106787 | COMPOSITION COMPRISING LACTIC ACID BACTERIA FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF RECURRENT CYSTITIS - A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis. | 2016-04-21 |
20160106788 | SYNBIOTIC MIXTURE - A preparation includes N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic | 2016-04-21 |
20160106789 | Inhibition of Neurodegenerative Disease by Grape Seed Extract, Green Tea Extract and Probiotic Bacteria - A composition is provided comprising extracts of at least grape seeds (GSE) and green tea. The extracts are preferably polyphenolic and preferably comprise probiotic bacteria. The use of extracts from green tea and grape seeds for the manufacture of a medicament against a neurodegenerative disease is also disclosed. | 2016-04-21 |
20160106790 | METHODS OF IMPROVING REPRODUCTIVE AND RESPIRATORY HEALTH - The present invention encompasses methods of improving reproductive and respiratory health. | 2016-04-21 |
20160106791 | PROBIOTIC BEVERAGE CONTAINING LIVING MYCELIUM AND METHOD OF PREPARATION - Humans have utilized mushrooms and mycelium for thousands of years. Currently mycelium is consumed at large in the form of dried powders in supplements. This patent describes a method for preparing a probiotic beverage containing living mycelium. This method allows the delivery of living mycelium through a water-sweetener-flavor base. Due to the living form of the mycelium and the consumable substrate this method is able to provide the beneficial properties of mycelium without degradation of the mycelium's beneficial properties. | 2016-04-21 |
20160106792 | TREATMENT OF CANCER - Methods of treating colorectal cancer using water extracts derived from | 2016-04-21 |
20160106793 | COMPOSITIONS AND METHODS FOR CONTROLING CARBOHYDRATE AND FAT METABOLISM - The subject of the invention is a composition comprising at least a mixture of molecules obtained at least from:
| 2016-04-21 |
20160106794 | NEW FRACTION OF SAGE EXTRACT AND USES THEREOF - The present invention relates to a new fraction of sage extract in which only traces of rosmarinic acid, carnosic acid and derivatives thereof and resins are present, a process for the preparation of such extract, compositions comprising it, and the use of the extract fraction and of the compositions for the protection of the skin or mucous membranes. | 2016-04-21 |
20160106795 | Methods and Compositions for Treating Skin - A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor. | 2016-04-21 |
20160106796 | HERBAL SUPPLEMENTS AND METHODS OF USE THEREOF - In one embodiment, the present application provides an herbal supplement and method for treating bloating, constipation and/or weight gain in a human subject comprising orally administering to a subject in need thereof an effective amount of the herbal supplement comprising a red quebracho extract. In other embodiments, the supplement may additionally include a triterpenoid saponin, an anti-spasmodic agent, or both. | 2016-04-21 |
20160106797 | TOPICAL TREATMENT OF SHINGLES - The present invention relates to a homeopathic composition that may be used for treatment of chronic moderate to severe pain associated with virally driven neuropathies. More particularly, the present disclosure and claims provide a treatment of the pain symptoms of shingles, herpes zoster. In some embodiments, the application of the homeopathic composition may reduce length of the outbreak, severity of symptoms, and long term effects, such as nerve damage or skin discoloration. | 2016-04-21 |
20160106798 | TOPICAL TREATMENT FOR USE IN CONJUNCTION WITH ACUPUNCTURE OR ACUPRESSURE THERAPY - The present invention relates to a topical application of a homeopathic composition to the skin to be used as an enhancement for acupuncture and acupressure. The composition may be in the form of an ointment, cream, gel, or salve. The composition may be applied before, during, and after acupressure or acupuncture. The composition may contain snake venom along with a synergistic blend of vasodilator and analgesic herbs that relieve pain by stimulating blood flow and reducing edema. The composition complements the Chinese medicine theory of balancing the body's energy flow. | 2016-04-21 |
20160106799 | Carbohydrate Compounds for Nutritional and Therapeutic Use - Embodiments of the present invention provide compositions and methods for the modulation of sialic acid levels. In some embodiments, compositions disclosed herein comprise nutraceuticals as functional agents. | 2016-04-21 |
20160106800 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE - The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2016-04-21 |
20160106801 | WOUND HEALING AGENT - The present invention aims to provide a wound healing agent that inhibits bacterial growth, promotes granulation tissue formation and epithelization, and minimizes foreign body reaction in the granulation tissue. The wound healing agent of the present invention contains protein (A) and water, wherein the protein (A) contains: GAGAGS (1); and an amino acid sequence (X) and/or an amino acid sequence (X′), and the total percentage of β turns and random coils in the protein (A) as determined by circular dichroism spectroscopy is 60 to 85%, and the percentage of the total number of amino acid residues in the amino acid sequences (X) and (X′) is 50 to 70% of the total number of amino acid residues in the protein (A). Amino acid sequence (X): at least one amino acid sequence selected from the group consisting of VPGVG (2), GVGVP (3), and GAHGPAGPK (4). Amino acid sequence (X′): an amino acid sequence in which 1 or 2 amino acid residues in the amino acid sequence (X) are independently replaced by a lysine (K) or arginine (R) residue. | 2016-04-21 |
20160106802 | METHODS OF DIAGNOSING AND TREATING ASTHMA - The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject. The present invention also provides methods and compositions for treating asthma that comprise one or more zonulin antagonist. | 2016-04-21 |
20160106803 | USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS - The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof. | 2016-04-21 |
20160106804 | Pharmaceutical composition with improved stability - The present invention provides an injectable composition for controlled release drug delivery and the process of making the same, where the composition comprises: a lactate-based polymer having a weight average molecular weight between 5,000 and 50,000 dalton, an acid number of less than 3 mgKOH/g and the content of residual lactide monomers in the lactate-based polymer of less than about 0.3% by weight; a pharmaceutically acceptable organic solvent; and a bioactive substance or a salt thereof that contains an amino acid serine in the molecular structure that is capable of reacting with lactide monomer to form a conjugate; and where the composition reduces the formation of the conjugate. | 2016-04-21 |
20160106805 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY - The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. | 2016-04-21 |
20160106806 | GLA DOMAINS AS TARGETING AGENTS - The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. | 2016-04-21 |
20160106807 | Method of Treatment - The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans. | 2016-04-21 |
20160106808 | Treatment of Mood and Anxiety Disorders - As follows from the Background section, above, there is a need in the art for improved methods for the treatment of mood and/or anxiety disorders. The present disclosure provides therapeutic agents and methods for treating mood (e.g., Major Depressive Disorder) and anxiety disorders (e.g., OCD, PTSD). In certain aspects, the present disclosure provides a method for treating a human patient for a mood or anxiety disorder, which comprises intranasally administering to a human patient in need of such treatment a composition comprising a therapeutically effective amount of neuropeptide Y (NPY) for reducing or eliminating the symptoms (or one more of the symptoms) of the mood or anxiety disorder. | 2016-04-21 |
20160106809 | METHODS OF TREATING CANCER - Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided. | 2016-04-21 |
20160106810 | Method for Inhibiting HIV Replication in Mammal and Human Cells - The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton. | 2016-04-21 |
20160106811 | METHOD FOR REPAIRING NEURODEGENERATION - The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof. | 2016-04-21 |
20160106812 | TREATMENT OF CANCER WITH IMMUNE STIMULATORS - The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents. | 2016-04-21 |
20160106813 | CGRP RECEPTOR AGONIST FOR HIV TREATMENT OR PREVENTION - A first object of the invention is CGRP or an agonist of the CGRP receptor for use in the prevention of an HIV infection in a human subject. A second object of the invention is a method for selecting an active compound for the prevention of an HIV infection in a human subject, comprising the steps of: a) contacting Langerhans cells with a candidate compound; b) in vitro infecting of Langerhans cells from step a) by at least one HIV variant, c) measuring of at least one of the following parameters: HIV content, adhesive potential of Langerhans cells, in particular to TCs, secretion of anti-HIV chemokines by Langerhans cells. A third object of the invention is therefore a composition comprising CGRP or agonist of the CGRP receptor for use in the prevention of an HIV infection in a human subject. A fourth object of the invention is a method for the in vitro diagnosis of an HIV infection in a human subject, characterized in that it comprises determining the level of CGRP from a biological sample from said subject. A fifth object of the invention is a method for assaying the efficiency of HAART in the treatment of HIV infection in a subject, characterized in that it comprises determining the level of CGRP from a biological sample from said subject. | 2016-04-21 |
20160106814 | Novel Oral Pharmaceutical Composition for Treatment of Diabetes - The invention provides improved solid oral pharmaceutical compositions comprising an insulin peptide or GLP-1 peptide and methods of producing such. | 2016-04-21 |
20160106815 | TREATMENT OF BLEEDING WITH LOW HALF-LIFE FIBRINOGEN - The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable. | 2016-04-21 |
20160106816 | TOPICAL THERAPEUTIC FORMULATIONS - The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites. | 2016-04-21 |
20160106817 | TREATMENT FOR BK POLYOMAVIRUS INFECTION - The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen. | 2016-04-21 |
20160106818 | HUMAN COAGULATION FACTOR LIGHT CHAIN PROTEIN AND USE OF THE SAME - In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The human coagulation factor light-chain proteins are light chain proteins of human coagulation factors VII, IX, and X, as well as a protein having homology of more than 50% thereof. | 2016-04-21 |
20160106819 | RIBOTOXIN MOLECULES DERIVED FROM SARCIN AND OTHER RELATED FUNGAL RIBOTOXINS - The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition. | 2016-04-21 |
20160106820 | VACCINE COMPOSITION - There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus. | 2016-04-21 |
20160106821 | FUNCTIONAL GHRELIN RECEPTOR ANTAGONISM DURING PREGNANCY TO PREVENT STRESS-ASSOCIATED MENTAL ILLNESS IN OFFSPRING AND MOTHERS - The invention relates to methods of protecting against elevated ghrelin levels in a fetus by antagonizing ghrelin or ghrelin receptor. The invention also encompasses methods of treating postpartum depression by administering ghrelin antagonists. | 2016-04-21 |
20160106822 | PCSK9 PEPTIDE COMBINATION VACCINE AND METHOD OF USE - The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9). | 2016-04-21 |
20160106823 | IMMUNITY INDUCTION AGENT - Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). Further, an in vitro method for preparing an antigen-presenting cell is provided. The method includes the step of contacting the antigen-presenting cell with the at least one polypeptide selected from: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). | 2016-04-21 |
20160106824 | YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS - Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury. | 2016-04-21 |